Magellan Asset Management Ltd Raises Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Magellan Asset Management Ltd increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 18.6% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 600,125 shares of the medical equipment provider’s stock after acquiring an additional 94,224 shares during the quarter. Magellan Asset Management Ltd owned about 0.30% of Zimmer Biomet worth $59,112,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in ZBH. Key Financial Inc raised its position in shares of Zimmer Biomet by 164.6% in the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares during the period. Cullen Frost Bankers Inc. grew its stake in Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 116 shares in the last quarter. Root Financial Partners LLC bought a new stake in Zimmer Biomet during the 3rd quarter valued at $31,000. Cary Street Partners Investment Advisory LLC raised its holdings in Zimmer Biomet by 83.7% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 149 shares during the period. Finally, Mather Group LLC. purchased a new stake in shares of Zimmer Biomet during the third quarter worth $36,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Up 0.5%

ZBH stock opened at $99.92 on Wednesday. The company’s 50 day moving average is $90.96 and its 200 day moving average is $95.90. The stock has a market cap of $19.55 billion, a price-to-earnings ratio of 28.23, a price-to-earnings-growth ratio of 2.03 and a beta of 0.62. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. Zimmer Biomet Holdings, Inc. has a 1-year low of $84.59 and a 1-year high of $114.44.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The business had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 27.12%.

Analyst Ratings Changes

A number of analysts recently issued reports on ZBH shares. Robert W. Baird reiterated a “neutral” rating and set a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Citigroup reissued a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, February 11th. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. Finally, Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and upped their target price for the stock from $94.00 to $120.00 in a report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $106.20.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.